PMID- 25099160
OWN - NLM
STAT- MEDLINE
DCOM- 20160119
LR  - 20240515
IS  - 1478-6362 (Electronic)
IS  - 1478-6354 (Print)
IS  - 1478-6354 (Linking)
VI  - 16
IP  - 4
DP  - 2014 Aug 6
TI  - Discriminant validity, responsiveness and reliability of the arthritis-specific 
      Work Productivity Survey assessing workplace and household productivity within 
      and outside the home in patients with axial spondyloarthritis, including 
      nonradiographic axial spondyloarthritis and ankylosing spondylitis.
PG  - R164
LID - 10.1186/ar4680 [doi]
LID - R164
AB  - INTRODUCTION: The arthritis-specific Work Productivity Survey (WPS) was developed 
      to evaluate productivity limitations associated with arthritis within and outside 
      the home. There is an unmet need for an instrument assessing similar productivity 
      limitations in axial spondyloarthritis (axSpA), including nonradiographic axSpA 
      and ankylosing spondylitis. Following its validation in rheumatoid and psoriatic 
      arthritis, we aimed to assess psychometric properties of WPS in adult-onset 
      active axSpA in this analysis. METHODS: Psychometric properties were assessed 
      using data from the RAPID-axSpA trial (NCT01087762) in which researchers 
      investigated certolizumab pegol efficacy and safety in axSpA. WPS was completed 
      at baseline and every 4 weeks until week 24. Validity was evaluated at study 
      baseline via known-groups defined by the first and third quartile cutoffs of 
      patient scores to Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath 
      Ankylosing Spondylitis Disease Activity Index (BASDAI), back pain, Bath 
      Ankylosing Spondylitis Functional Index (BASFI), Short Form 36 health survey 
      (SF-36) and Ankylosing Spondylitis Quality of Life Scale (ASQoL). Responsiveness 
      and reliability were assessed by comparing WPS mean changes in ASAS 20% 
      improvement criteria (ASAS20), BASDAI50, ASDAS clinically important 
      improvement/major improvement (CII/MI) and BASFI minimum clinically important 
      difference (MCID) responders versus nonresponders at week 12. All comparisons 
      were conducted on observed cases in the randomized set using a nonparametric 
      bootstrap-t method. RESULTS: The results confirmed the psychometric properties of 
      WPS. AxSpA patients with a worse health state had significantly more days of 
      household work lost, household work with reduced productivity, social activities 
      missed and outside help hired, as well as a higher interference rate of 
      arthritis, than patients with a better health state. Similarly, employed patients 
      with a worse health state had significantly more work days lost or with 
      productivity reduced, and a higher interference of arthritis on work 
      productivity. Similar findings were also observed in the nonradiographic (nr) 
      axSpA and AS subpopulations. The WPS was responsive to clinical changes, with 
      responders reporting larger improvements at week 12 in WPS scores versus 
      nonresponders. Effect sizes in responders were generally moderate to large 
      (standardized response mean >0.5). CONCLUSIONS: These analyses demonstrate that 
      WPS is a valid, responsive and reliable instrument for the measurement of 
      productivity within and outside the home in adult-onset axSpA, as well as the in 
      subpopulations of AS and nr-axSpA.
FAU - Osterhaus, Jane T
AU  - Osterhaus JT
AD  - Wasatch Health Outcomes, 2613 Silver Cloud Drive, Park City, UT, 84060, USA. 
      jtosterhaus@mindspring.com.
FAU - Purcaru, Oana
AU  - Purcaru O
AD  - UCB Pharma, Allee de la Recherche, 60, 1070, Brussels, Belgium. 
      Oana.Purcaru@ucb.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140806
PL  - England
TA  - Arthritis Res Ther
JT  - Arthritis research & therapy
JID - 101154438
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Immunosuppressive Agents)
RN  - UMD07X179E (Certolizumab Pegol)
SB  - IM
MH  - Adult
MH  - Certolizumab Pegol/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunoglobulin Fab Fragments/therapeutic use
MH  - Immunosuppressive Agents/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Psychometrics
MH  - *Quality of Life
MH  - Reproducibility of Results
MH  - Spondylarthritis/*drug therapy/psychology
MH  - Spondylitis, Ankylosing/*drug therapy/psychology
MH  - *Workplace
PMC - PMC4448884
EDAT- 2014/08/08 06:00
MHDA- 2016/01/20 06:00
PMCR- 2014/08/06
CRDT- 2014/08/08 06:00
PHST- 2013/12/19 00:00 [received]
PHST- 2014/07/22 00:00 [accepted]
PHST- 2014/08/08 06:00 [entrez]
PHST- 2014/08/08 06:00 [pubmed]
PHST- 2016/01/20 06:00 [medline]
PHST- 2014/08/06 00:00 [pmc-release]
AID - ar4680 [pii]
AID - 4379 [pii]
AID - 10.1186/ar4680 [doi]
PST - epublish
SO  - Arthritis Res Ther. 2014 Aug 6;16(4):R164. doi: 10.1186/ar4680.